Background
Methods
Study design
Searching strategies and selection criteria
Data extraction
Statistical analysis
Results
Studies characteristics
Variant | Study | Country | Ethnicity | n (cases/control) | Source of controls | Type of diabetes | Genotyping methods | DMC | Method of DR acertainment | NOS |
---|---|---|---|---|---|---|---|---|---|---|
UCP1 rs1800592 | Jin 2017 | China | Han Chinese | 1875 (530/1345) | Population-based study | T2DM | MassARRAY | DR | Direct ophthalmoscopy, fundus fluorescein angiography and OCT | 7 |
Jin 2020 | China | Han Chinese | 1235 (134/1101) | Hospital-based case-control | T2DM | Affymetrix Genome-Wide Human SNP Array 6.0 | DR | Direct ophthalmoscopy, fundus fluorescein angiography and OCT | 7 | |
Montesanto 2018 | Italy | European | 940 (435/505) | Population-based study | T2DM | MassARRAY | DR | Fundoscopy through dilated pupils and/or fluorescein angiography | 6 | |
Rudofsky 2007 | Germany | Caucasian | 517 (128/389) | Hospital-based case-control | T2DM | PCR-RFLPs | DR | Fundoscopy, indirect ophthalmoscopy and fundus fluorescein angiography | 8 | |
Zhang 2014 | China | Han Chinese | 792 (488/344) | Hospital-based case-control | T2DM | PCR-LDR | NPDR, PDR | Fundoscopy and fundus fluorescein angiography | 8 | |
Zietz 2006 | Germany | Caucasian | 509 (194/315) | Population-based study | T2DM | PCR-RFLPs | NPDR, PDR | Fundus photograpy | 5 | |
Brondani 2012 | Brazil | European | 257 (154/103) | Hospital-based case-control | T1DM | PCR-RFLPs | DR | Fundoscopy through dilated pupils | 6 | |
Rudofsky 2006 | Germany | Caucasian | 227 (64/163) | Hospital-based case-control | T1DM | PCR-RFLPs | DR | Ophthalmoscopic examination | 7 | |
UCP2 rs659366 | Crispim 2010 | Brazil | European | 501 (242/259) 196 (85/111) | Hospital-based case-control | T1DM, T2DM | PCR-RFLPs | PDR | Fundoscopy through dilated pupils | 7 |
Jin 2017 | China | Han Chinese | 1875 (530/1344) | Population-based study | T2DM | MassARRAY | DR | Direct ophthalmoscopy, fundus fluorescein angiography and OCT | 7 | |
Jin 2020 | China | Han Chinese | 1235 (134/1101) | Hospital-based case-control | T2DM | Affymetrix Genome-Wide Human SNP Array 6.0 | DR | Direct ophthalmoscopy, fundus fluorescein angiography and OCT | 7 | |
Rudofsky 2007 | Germany | Caucasian | 645 (128/517) | Hospital-based case-control | T2DM | PCR-RFLPs | DR | Fundoscopy, indirect ophthalmoscopy and fundus fluorescein angiography | 8 | |
Shen 2014 | China | Han Chinese | 472 (317/155) | Hospital-based case-control | T2DM | ABI 3100 genetic analyzer | NPDR, PDR | Fundoscopy through dilated pupils | 5 | |
Zhou 2018 | China | Han Chinese | 408 (209/199) | Hospital-based case-control | T2DM | ABI 3730 genetic analyzer | NPDR, PDR | Fundoscopy and fundus photograpy | 6 | |
Rudofsky 2006 | Germany | Caucasian | 227 (64/163) | Hospital-based case-control | T1DM | PCR-RFLPs | DR | Ophthalmoscopic examination | 7 |
Variant | Controls (n) | Cases (n) | Study | Cases | Controls | PHWE | MAF | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCP1 rs1800592 | GG | GA | AA | G | A | GG | GA | AA | G | A | |||||
DWR (2260) | DR (1386) | Jin 2017 | 140 | 251 | 139 | 531 | 529 | 338 | 669 | 338 | 1345 | 1345 | 0.85 | 50% | |
Rudofsky 2007 | 5 | 63 | 60 | 73 | 183 | 18 | 173 | 198 | 209 | 569 | 0.01 | 27% | |||
Zhang 2014 | 122 | 217 | 105 | 461 | 427 | 79 | 161 | 94 | 319 | 349 | 0.53 | 50% | |||
Zietz 2006 | 8 | 72 | 114 | 88 | 300 | 15 | 117 | 183 | 147 | 483 | 0.50 | 23% | |||
DWR (649) | NPDR (366) | Zhang 2014 | 57 | 110 | 60 | 224 | 230 | 79 | 161 | 94 | 319 | 349 | 0.53 | 48% | |
Zietz 2006 | 6 | 49 | 84 | 61 | 217 | 15 | 117 | 183 | 147 | 483 | 0.50 | 23% | |||
DWR (649) | PDR (272) | Zhang 2014 | 65 | 107 | 45 | 237 | 197 | 79 | 161 | 94 | 319 | 349 | 0.53 | 50% | |
Zietz 2006 | 2 | 23 | 30 | 27 | 83 | 15 | 117 | 183 | 147 | 483 | 0.50 | 24% | |||
UCP2 rs659366 | AA | AG | GG | A | G | AA | AG | GG | A | G | |||||
DWR (2244) | DR (1236) | Jin 2017 | 68 | 261 | 201 | 397 | 663 | 177 | 654 | 513 | 1008 | 1680 | 0.16 | 37% | |
Rudofsky 2007 | 17 | 62 | 49 | 96 | 160 | 49 | 186 | 154 | 284 | 494 | 0.54 | 37% | |||
Shen 2014 | 59 | 144 | 102 | 262 | 348 | 38 | 73 | 38 | 149 | 149 | 0.81 | 45% | |||
Zhou 2018 | 57 | 122 | 30 | 236 | 182 | 33 | 110 | 56 | 176 | 222 | 0.09 | 50% | |||
DWR (348) | NPDR (194) | Shen 2014 | 23 | 54 | 25 | 100 | 104 | 38 | 73 | 38 | 149 | 149 | 0.81 | 50% | |
Zhou 2018 | 25 | 61 | 6 | 111 | 73 | 33 | 110 | 56 | 176 | 222 | 0.09 | 49% | |||
DWR (606) | PDR (560) | Crispim 2010 | 45 | 131 | 64 | 221 | 259 | 30 | 116 | 112 | 176 | 340 | 1.00 | 40% | |
Shen 2014 | 36 | 90 | 77 | 162 | 244 | 38 | 73 | 38 | 149 | 149 | 0.81 | 44% | |||
Zhou 2018 | 32 | 61 | 24 | 125 | 109 | 33 | 110 | 56 | 176 | 222 | 0.09 | 48% |
Data analysis
Comparison | Variant | Model | Effect | Pooled OR (95% C.I.) | Z | Pz | I2 | P for heterogeneity |
---|---|---|---|---|---|---|---|---|
DR vs DWR | UCP1 rs1800592 | Allelic (G vs A) | Fixed | 1.03 (0.93, 1.13) | 0.51 | 0.609 | 0.0% | 0.533 |
Homozygous (GG vs AA) | Fixed | 1.10 (0.88, 1.37) | 0.85 | 0.398 | 0.0% | 0.375 | ||
Heterozygous (AG vs AA) | Fixed | 1.00 (0.84, 1.19) | 0.01 | 0.992 | 0.0% | 0.431 | ||
Dominant (GG + AG vs AA) | Fixed | 1.03 (0.87, 1.21) | 0.31 | 0.760 | 8.6% | 0.335 | ||
Recessive (GG vs AG + AA) | Fixed | 1.11 (0.92, 1.33) | 1.07 | 0.284 | 0.0% | 0.684 | ||
DR vs DWR | UCP2 rs659366 | Allelic (A vs G) | Random | 1.00 (0.79, 1.27) | 0.02 | 0.983 | 79.3% | 0.001 |
Homozygous (AA vs GG) | Random | 1.17 (0.63, 2.17) | 0.49 | 0.623 | 82.7% | 0.001 | ||
Heterozygous (GA vs GG) | Random | 1.10 (0.79, 1.55) | 0.56 | 0.572 | 66.8% | 0.029 | ||
Dominant (AA+GA vs GG) | Random | 1.12 (0.75, 1.67) | 0.55 | 0.584 | 78.4% | 0.003 | ||
Recessive (AA vs GA + GG) | Random | 1.07 (0.73, 1.57) | 0.35 | 0.73 | 66.1% | 0.031 |
Variant | Cases vs Controls | Ethnicity | Allelic | Homozygous | Heterozygous | Dominant | Recessive |
---|---|---|---|---|---|---|---|
OR (95% C.I.) | OR (95% C.I.) | OR (95% C.I.) | OR (95% C.I.) | OR (95% C.I.) | |||
UCP1 rs1800592 | G vs A | GG vs AA | AG vs AA | GG + AG vs AA | GG vs AG + AA | ||
NPDR vs DWR | 1.02 (0.84,1.23) | 1.08 (0.71,1.64) | 0.99 (0.74,1.33) | 1.00 (0.76,1.32) | 1.05 (0.73,1.52) | ||
PDR vs DWR | 1.26 (1.02,1.56)* | 1.60 (1.01,2.52)* | 1.32 (0.93, 1.87) | 1.38 (0.99,1.92) | 1.32 (0.91,1.92) | ||
UCP2 rs659366 | A vs G | AA vs GG | GA vs GG | AA+GA vs GG | AA vs GA + GG | ||
NPDR vs DWR | 1.36 (0.69,2.67) | 2.48 (0.33, 18.37) | 2.33 (0.51,10.57) | 2.35 (0.45, 12.43) | 1.26 (0.58,2.75) | ||
PDR vs DWR | 1.17 (0.67,2.05) | 1.40 (0.46,4.24) | 1.17 (0.57,2.40) | 1.22 (0.54,2.77) | 1.28 (0.63,2.56) | ||
UCP1 rs1800592 | G vs A | GG vs AA | AG vs AA | GG + AG vs AA | GG vs AG + AA | ||
DR vs DWR | Chinese | 1.05 (0.94, 1.16) | 1.12 (0.89,1.40) | 1.00 (0.82,1.22) | 1.04 (0.86,1.26) | 1.12 (0.93,1.35) | |
Total | 1.03 (0.93, 1.13) | 1.10 (0.88,1.37) | 1.00 (0.84,1.19) | 1.03 (0.87,1.21) | 1.11 (0.92, 1.33) | ||
UCP2 rs659366 | A vs G | AA vs GG | GA vs GG | AA+GA vs GG | AA vs GA + GG | ||
DR vs DWR | Chinese | 0.99 (0.74, 1.34) | 1.20 (0.52,2.76) | 1.13 (0.70,1.83) | 1.15 (0.65,2.03) | 1.08 (0.65,1.77) | |
Total | 1.00 (0.79,1.27) | 1.17 (0.63,2.17) | 1.10 (0.79,1.55) | 1.12 (0.75,1.67) | 1.07 (0.73,1.57) |
Evaluation of publication bias and sensitivity analyses
Variant | Cases vs Controls | Allelic | Homozygous | Heterozygous | Dominant | Recessive |
---|---|---|---|---|---|---|
UCP1 rs1800592 | DR vs DWR | 0.482 | 0.970 | 0.520 | 0.657 | 0.763 |
UCP2 rs659366 | DR vs DWR | 0.944 | 0.687 | 0.710 | 0.702 | 0.770 |